Koenig Sheldon L. 4

What Happened
Sheldon L. Koenig, President, CEO and a director of Esperion Therapeutics (ESPR), reported a sale of 25,578 shares on 2026-03-17 at $2.72 per share, for total proceeds of $69,547. The filing shows this was a sale (Disposition) and the shares were sold to satisfy tax withholding on vested restricted stock units (RSUs).

Key Details

• Transaction date: 2026-03-17 (reported on Form 4 filed 2026-03-18)
• Transaction type: Sale (code S) — open market or private sale reported
• Price and amount: 25,578 shares at $2.72 each; total value $69,547
• Footnote: Shares sold to satisfy tax obligation on vested RSUs (tax withholding)
• Shares owned after transaction: Not specified in the provided filing excerpt
• Timeliness: Form 4 filed the day after the transaction (within typical reporting window)

Context
Sales to cover taxes on vested RSUs are common and usually routine (reflecting tax withholding), and do not by themselves indicate the insider’s longer-term view of the company. For retail investors, purchases by insiders tend to be more informative about bullish conviction; this report documents a routine tax-related sale.